Zacks Investment Research downgraded shares of STEMLINE THERAP (STML) from OUTPERFORM to NEUTRAL on November 12, 2014, with a target price of $17.30.
Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on STEMLINE THERAP (STML),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment